TY - CHAP
T1 - 18F-FDG PET for Neurodegenerative Diseases
T2 - Principles and Progress
AU - Thientunyakit, Tanyaluck
AU - Wannasoupol, Nantika
AU - Sethanandha, Chakmeedaj
AU - Piyapittayanan, Siriwan
AU - Siriprapa, Tossaporn
AU - Thongpraparn, Thonnapong
AU - Muangpaisan, Weerasak
AU - Gelovani, Juri
N1 - Publisher Copyright:
© The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 2025.
PY - 2025
Y1 - 2025
N2 - The prevalence of neurodegenerative diseases has been increasing in aging society. Recent developments in several biomarkers help understand the underlying principles of neurodegenerative diseases and accelerate remarkable progress in clinical practice and research. Here, we describe a prospective study on the use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) of the brain as a predictive marker for response to treatment in patients with Alzheimer’s disease and compare results with other imaging markers, including amyloid PET, MRI, and the integrated imaging marker using amyloid PET, FDG PET, and MRI. We aim to provide the readers with guidelines on applying both qualitative and semiquantitative and integrating FDG PET data with other imaging markers. The research challenges and possible measures to overcome those challenges are also discussed.
AB - The prevalence of neurodegenerative diseases has been increasing in aging society. Recent developments in several biomarkers help understand the underlying principles of neurodegenerative diseases and accelerate remarkable progress in clinical practice and research. Here, we describe a prospective study on the use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) of the brain as a predictive marker for response to treatment in patients with Alzheimer’s disease and compare results with other imaging markers, including amyloid PET, MRI, and the integrated imaging marker using amyloid PET, FDG PET, and MRI. We aim to provide the readers with guidelines on applying both qualitative and semiquantitative and integrating FDG PET data with other imaging markers. The research challenges and possible measures to overcome those challenges are also discussed.
KW - Alzheimer’s disease
KW - F-FDG PET
KW - F-fluorodeoxyglucose
KW - Neurodegenerative diseases
KW - Neuroimaging
KW - Positron emission tomography
KW - Treatment response
UR - https://www.scopus.com/pages/publications/105004241491
U2 - 10.1007/978-1-0716-4494-2_6
DO - 10.1007/978-1-0716-4494-2_6
M3 - Chapter
AN - SCOPUS:105004241491
T3 - Neuromethods
SP - 85
EP - 105
BT - Neuromethods
PB - Humana Press Inc.
ER -